Share
8,977 Posts.
lightbulb Created with Sketch. 1763
clock Created with Sketch. 19/03/21
12:08
Share
Originally posted by Densy:
↑
I believe this is probably correct adreamer, however, it seems to me that the company could have / should have provided an update clearly addressing the solubility issues referenced as recently as 8 January this year as contributting to testing delays:more research is being undertaken at LUMC to increase the solubility of MPL, as a precursor to MPL demonstrating applicability against coronavirus.finding conditions that are compatible with the highly specialised assays and coronavirus culture conditions for testing MPL. These assays and this development program are crucial for later performing work in more advanced human airway systems." What I understand form this update is:finding ' conditions implies that those condition had not been found at the time of the market update.later '.The studies have now commenced and the final data report is exepcted imminently. " but it is unclear which 'studies' are being referenced (efficacy, solubility??) or whether the solubility issue had been fixed or even identified during the quarter. If these words are meant to convey that the solubility has been fixed since 8 January and the testing was back on track, it should be made clear that the company is reporting something that has occurred subsequent to the period the update relates to. Tests using monepantel and monepantel sulfone as Covid-19 antivirals, however, continue at Leiden University and PharmAust will be pleased to update the market when results come to hand. "
Expand
PAA have used this tactic over many years, always leaving shareholders in the dark to what progress if any is being made.
(20min delay)